sgn-ceacam5c
mAbexperimentalADC
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 20, 2023 (NCT06131840)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
CEACAM5 binding agent
Chemistry & pharmacology
- Payload
- MMAE
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06131840 | Phase 1 | Nov 20, 2023 | Sanofi, Seattle Genetics |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 1 | 0 | 1 | 2023 |
| Seattle Genetics | For profit | 1 | 1 | 1 | 2023 |
2 organizations
Page 1 / 1